Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Stimulus-Funded CER: Few Awards Are For Drug Vs. Drug Studies

Executive Summary

Pitting one drug against another proved not to be a key focus of the comparative effectiveness research funding given from the $1.1 billion set aside for CER in the American Recovery and Reinvestment Act.

You may also be interested in...

House Committee Questions HHS On Spending Of Comparative Effectiveness Research Funds

The Energy and Commerce Committee's investigation is an example of the close scrutiny of CER activities expected of the Republican-controlled House.

CER To Play A Larger Role In Investment Decisions – Merck's McElwee

Pharmaceutical companies are going to need to consider the impact of the growing emphasis on comparative effectiveness earlier in the drug development and investment decision process, Merck & Co.'s Newell McElwee said.

Comparative Effectiveness Infrastructure Is Priority, Federal Advisors Say

Both the Institute of Medicine and the Federal Coordinating Council for Comparative Effectiveness Research are placing a high priority on building an infrastructure around comparative effectiveness to facilitate the research as well as the dissemination of findings





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts